Skip to main content

Optimizing miR-29 measurements in biobanked, heparinized samples.

Warnement CM, Cismowski MJ, Rogers LK

Publication: Life Sci (2019) • Page 116894PMID: 31626789View on PubMed

Purpose

This paper investigated the effects of heparinase treatment, freeze-thaw cycling, and hemoglobin concentration on levels of miR-29 isoforms in plasma.

Conclusion

miR-29 isoforms were not quantifiable in heparin plasma without heparinase treatment or after treatment with R&D heparinase III for 1 or 2 h, but cycle threshold (CT) values were within 1 cycle of those in EDTA plasma when plasma was treated for 1 or 2 h with R&D heparinase I or II or NEB heparinase I. Levels of miR-29b-3p were non-significantly lower in frozen than fresh specimens but were significantly lower in specimens freeze-thaw cycled 5 or 10 times than in fresh specimens. Levels of miR-29b-3p were not correlated with hemoglobin concentration.

Studies (1)

Purpose

This study investigated the effects of heparinase treatment, freeze-thaw cycling, and hemoglobin levels on levels of miR-29 isoforms in plasma. Plasma was obtained from the blood of three healthy volunteers in EDTA and Heparin tubes (processing details not provided). The effects of heparinase treatment were investigated by incubation of plasma with R&D systems recombinant F. heparinum heparinase I, recombinant P. heparinus heparinase II, and recombinant P. heparinus heparinase III or New England Biolabs (NEB) heparinase I. An aliquot of heparinase-treated plasma was removed after 1 h and another after 2 h. Plasma was analyzed fresh, after one freeze-thaw cycle (at -80°C for 72 h), and again after 5 and 10 freeze-thaw cycles. Hemoglobin levels were determined by ELISA. miR-29a-3p, miR-29a-5p, miR-29b2-5p, miR-29c-3p, and miR-29c-5p were quantified by real-time PCR.

Summary of Findings

miR-29 isoforms were not quantifiable in heparin plasma without heparinase treatment or after treatment with R&D heparinase III for 1 or 2 h, but CT values were within 1 cycle of those in EDTA plasma when plasma was treated for 1 or 2 h with R&D heparinase I or II, or NEB heparinase. Levels of miR-29b-3p were non-significantly lower in frozen than fresh specimens but were significantly lower in specimens freeze-thaw cycled 5 or 10 times than in fresh specimens (P=0.033 and P=0.020, respectively). Levels of miR-29b-3p were not correlated with hemoglobin concentration.

  • Biospecimens

    FluidPlasma
    FluidBlood
  • Preservation Types

    None (Fresh)Frozen
  • Diagnoses

    Normal
  • Platforms

    RNART-PCR
    ProteinELISA
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen AcquisitionAnticoagulant
    EDTA
    Heparin
    Biospecimen Aliquots and ComponentsHemolysis
    Present
    Biospecimen PreservationType of fixation/preservation
    Frozen
    None (fresh)
    StorageFreeze/thaw cycling
    0 cycles
    1 cycle
    10 cycles
    5 cycles
    RT-PCR SpecificTargeted nucleic acid
    Target miR-29-3p
    RT-PCR SpecificTemplate modification
    Treated with NEB heparinase I
    Treated with R&D systems recombinant F. heparinum heparinase I (I)
    Treated with R&D systems recombinant P. heparinus heparinase II (2)
    Treated with R&D systems recombinant P. heparinus heparinase III (3)
    Untreated